drugset / Trial / NCT00327470

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD

NCT00327470

Phase 4 Terminated 288 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established CNV. Additionally, the study would like to determine the efficacy of Macugen in preserving visual function in those subjects having CNV secondary to neovascular AMD.

Timeline

Start
2006-07
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer 0.3 mg